Arzerra Articles
Patent briefs: Yaz patent invalid; FDA bars generic OxyContin; Appeals court backs GSK over Arzerra
17 April 2013
GSK settles with Genentech over ofatumumab patents
28 March 2012
US court rules in GlaxoSmithKline’s favor in Arzerra patent dispute
18 November 2011
Negative decisions from UK’s NICE for Novartis’ Xolair, GSK’s Arzerra and Pfizer’s Torisel, but OK for Amgen’s Prolia
27 October 2010
UK’s NICE turns down PharmaMar’s Yondelis and GlaxoSmithKline’s Arzerra
20 September 2010
Denmark’s Genmab updates on corporate strategy; licenses ADC technology from Seattle Genetics
15 September 2010
GlaxoSmithKline amends ofatumumab deal with Genmab; sells Italian research center to Aptuit
2 July 2010
BioMarin launches LEMS drug Firdapse in European Union; and Genmab gets conditional approval for Arzerra
20 April 2010
EMEA proposes measures to better manage Tysabri’s PML risks; positive opinions from CHMP include two on GSK products
22 January 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
Loss down on rocketing sales for Genmab
15 May 2009
BLA submitted for GSK and Genmab's Arzerra
9 February 2009
Showing 1-22 of 22 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
